Misonix Inc. (NSDQ:MSON) spiked a U.S. distribution deal with Aesculap Inc. for its SonaStar surgical aspiration system, saying it will sell the device direct through its own sales operation.
The new arrangement becomes effective Oct. 18.
Misonix said it will use its 75-person sales force to market the device, which is used to remove hard and soft tumors during neurological and general surgeries.
In January, the Farmingdale, N.Y.-based firm struck a deal with medical device distributor Neuromed Chile SA to sell the SonaStar and BoneScalpel devices in Chile.
More recently, Center Valley, Pa.-based Aesculap logged a win with the Food & Drug Administration when it won 510(k) clearance for its S4 cervical occipital plating system last month.